Browse News
Filter News
Found 773,721 articles
-
The documents come just two days before an advisory committee is scheduled to vote on the Alzheimer’s drug.
-
Inventiva and Echosens launch joint initiative to increase NASH awareness and access to screening for at-risk patients
6/8/2023
Inventiva and Echosens announce their collaboration in raising awareness about NASH and increase access to screening for patients at risk of developing NASH.
-
Ionis prices private placement of convertible senior notes - June 08, 2023
6/8/2023
Ionis Pharmaceuticals, Inc. announced the pricing of $500.0 million aggregate principal amount of 1.75% Convertible Senior Notes due 2028 in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
-
Continued strong Cresemba® (isavuconazole) sales by Pfizer trigger USD 26 million sales milestone payments to Basilea
6/8/2023
Basilea Pharmaceutica Ltd, Allschwil, a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial or fungal infections, reported that sales of the antifungal Cresemba® by its license partner Pfizer in Europe and the Asia Pacific and China regions, respectively, exceeded thresholds that triggered two separate milestone payments totaling USD 26.25 million to Basilea.
-
SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies
6/8/2023
Innate Pharma SA is pleased to share Sanofi’s news that the U.S. Food and Drug Administration has granted Fast Track Designation for SAR’579 / IPH6101 for the treatment of hematological malignancies.
-
Pixium Vision announces receipt of € 1.8 million from the French Government as Research Tax Credit
6/8/2023
Pixium Vision announces receipt of € 1.8 million from the French Government as Research Tax Credit
-
Immune-Onc Therapeutics Presents IO-202 Phase 1 Data in Patients with Relapsed or Refractory AML and CMML at the EHA Annual Meeting 2023
6/8/2023
Immune-Onc Therapeutics, Inc. announced Phase 1 data for IO-202, a first-in-class humanized IgG1 monoclonal antibody targeting Leukocyte Immunoglobulin-Like Receptor B4.
-
Marketing Authorization Application for lecanemab as treatment for early Alzheimer's disease filed in South Korea
6/8/2023
BioArctic AB's partner Eisai announced that Eisai has submitted a marketing authorization application for lecanemab, an investigational anti-amyloid beta protofibril[1] antibody, for the treatment of early Alzheimer's disease[2] with confirmed amyloid pathology in the brain, to the Ministry of Food and Drug Safety in South Korea.
-
GE HealthCare Technologies Inc. Prices Secondary Offering of 25,000,000 Shares
6/8/2023
GE HealthCare Technologies Inc. announced the pricing of the previously announced secondary underwritten public offering of 25,000,000 shares of its common stock at a public offering price of $78.00 per share.
-
EpimAb Biotherapeutics Appoints Yonghong Zhu, M.D., Ph.D., as Chief Medical Officer
6/8/2023
EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies, announced the appointment of Yonghong Zhu, M.D., Ph.D., as Chief Medical Officer.
-
Burning Rock's precision oncology diagnostics product supports advancement in late-stage breast cancer treatment, with results published in the New England Journal of Medicine
6/8/2023
Burning Rock Biotech Limited is pleased to announce that our flagship comprehensive genomic profiling product, OncoScreenTM Plus, was featured in a phase 3 multi-regional clinical trial, along with FoundationOneCDx, in support of advancement in breast cancer treatment.
-
Annual General Meeting 2023
6/8/2023
ObsEva SA, a biopharmaceutical company developing novel therapies for women's health, published the invitation to its 2023 Annual General Meeting of Shareholders to be held on June 29, 2023, at 10:30 CEST at the company's offices in Geneva, Chemin des Aulx 12, 3rd floor, 1228 Plan-les-Ouates, Switzerland.
-
Akoya Biosciences Announces Pricing of Public Offering of Common Stock - June 08, 2023
6/8/2023
Akoya Biosciences, Inc. announced the pricing of its public offering of 8,700,000 shares of common stock at a public offering price of $5.00 per share for gross proceeds of approximately $43.5 million, without giving effect to the underwriting discount and commission as well as estimated expenses payable by Akoya.
-
Qilu Pharmaceutical Announces Trials in Progress Posters on QL1706 in Phase III NSCLC Clinical Research at ASCO 2023
6/8/2023
Recently, Qilu Pharmaceutical presented a Trials in Progress poster presentation on QL1706, an innovative bifunctional antibody for immunotherapy, in two Phase III non-small cell lung carcinoma clinical studies at the 2023 American Society of Clinical Oncology Annual Meeting.
-
In a late-stage study of non-ambulatory patients with DMD on background corticosteroids, pamrevlumab failed to meet the primary endpoint for upper limb performance.
-
Promosome filed lawsuits Tuesday against Moderna and Pfizer/BioNTech, alleging that the vaccine developers used patent-protected mRNA technology without a license.
-
The Federal Trade Commission’s lawsuit takes an unusual strategy, according to legal experts, raising concerns and uncertainties in the biopharma industry.
-
Biosimilars effectively lowered cancer therapy Herceptin prices and made trastuzumab more accessible to patients, finds a new study from the USC Schaeffer Center.
-
DermTech Announces Contract With Hawaii Blues Plan for the Foundational Assay of Its DermTech Melanoma Test (DMT)
6/7/2023
DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced an agreement with a Blues plan in Hawaii.
-
Baudax Bio Announces Additional, Positive Top-Line Results From Phase 2 Randomized Clinical Trial of BX1000
6/7/2023
Baudax Bio, Inc. today announced additional results from its Phase 2 clinical trial of BX1000 for neuromuscular blockade (NMB) in patients undergoing elective surgery.